You are here: Industry Insights > Kymriah

News List

Scottish Medicines Consortium approves Kymriah® CAR-T therapy europeanpharmaceuticalreview
September 12, 2019
The Kymriah (tisagenlecleucel) treatment has received a positive appraisal from the Scottish Medicines Consortium, after EMA approval last year.
Novartis' Kymriah to be covered by Japan's national insurance system pharmafile
May 17, 2019
Japan’s national medical insurance system will pay for Novartis’ CAR-T therapy Kymriah following approval from the Central Social Insurance Medical Council.
Medicare proposal will increase payments for CAR-T cell therapies Yescarta, Kymriah firstwordpharma
April 25, 2019
The US Centers for Medicare and Medicaid Services (CMS) issued a proposal that would see an increase in payments for CAR-T cell therapies ...
NICE recommends NHS use of Kymriah for second indication pharmaceutical-technology
February 03, 2019
The UK’s pricing regulator the National Institute for Health and Care Excellence (NICE) has recommended Novartis’ CAR-T therapy Kymriah (tisagenlecleucel) for use by the National Health Service (NHS)
Novartis changes NICE's mind on Kymriah, giving CAR-T rival Gilead some company fiercepharma
February 01, 2019
Payer coverage is key to Novartis’ plan to get Kymriah going, and the company is going to be getting some more of that.
Gene therapy drug Kymriah should be publicly covered if manufacturer drops price, report recommends firstwordpharma
January 17, 2019
An expert panel convened by the Canadian Agency for Drugs and Technologies in Health (CADTH) concluded that Novartis' gene therapy Kymriah should be publicly covered provided the company lowers its price, The Globe and Mail reported.
Novartis offers to buy Kymriah manufacturer pharmaphorum
December 24, 2018
Following its success in the burgeoning area of CAR-T therapies, Novartis is looking to strengthen its cell and gene manufacturing capabilities by offering to acquire CDMO CellforCure, manufacturers of its CAR-T drug Kymriah.
Novartis, still struggling with Kymriah manufacturing, is providing some out-of-spec doses to patients who ask fiercepharma
December 19, 2018
Novartis released some new data on CAR-T drug Kymriah this month that it hopes will improve the uptake of the drug. But Novartis also continues to wrestle with manufacturing issues that have kept some doses from meeting specifications, a problem that is a
Nearly 300 gene and cell therapies in development – report pharmaphorum
December 10, 2018
Pharma is becoming increasingly focused on gene and cell therapies, with nearly 300 in clinical development or awaiting review by the FDA, according to a new report from US trade body PhRMA.
Novartis’ Kymriah shows ‘strong efficacy’, ‘durable response’ in new analysis pharmatimes
December 04, 2018
Novartis has released longer-term analyses of data from the ELIANA and JULIET trials showing that its CAR-T cell therapy Kymriah demonstrated “strong efficacy” and “durable responses” in certain blood cancer patients.

Previous page 1 2 3 4 Next page